Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252329 | 0.90 | PDGFRB (0.34) | PDE10AALOX5APFEN1PDGFRBKDR | |
| SCHEMBL30467616 | 0.89 | DHFR (0.41) | PDE10APDGFRBKDRLPLLIPG | |
| SCHEMBL24252713 | 0.89 | DHFR (0.41) | PDE10APDGFRBKDRLPLLIPG | |
| SCHEMBL24252837 | 0.82 | PDGFRB (0.34) | PDE10APDGFRBKDRDHFR | |
| SCHEMBL26771970 | 0.82 | DHFR (0.33) | PDE10AALOX5APFEN1PDGFRBKDR | |
| SCHEMBL25209984 | 0.82 | DHFR (0.33) | PDE10AALOX5APFEN1PDGFRBKDR | |
| SCHEMBL25242130 | 0.82 | DHFR (0.33) | PDE10AALOX5APFEN1PDGFRBKDR | |
| Trifluoroacetic Acid SCHEMBL30467704 | 0.81 | F2 (0.40) | PDE10APDGFRBKDRLIPGDHFR | |
| SCHEMBL29015460 | 0.81 | LPL (0.37) | LPLLIPGSNCACSF1R | |
| SCHEMBL24252749 | 0.79 | DHFR (0.38) | PDE10ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PDE10A 1950/4885ALOX5AP 246/4885FEN1 2638/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | PDE10A 1950/4885ALOX5AP 246/4885FEN1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.